Early Detection for Pancreatic Cancer: A Breakthrough in Blood Testing

Pancreatic cancer remains one of the most challenging malignancies to diagnose and treat, primarily because it typically presents at advanced stages when treatment options are limited. However, recent research offers new hope for early detection through a novel blood test that could significantly improve survival rates.

A New Hope: Four-Marker Blood Test

National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer, and the new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. Published in Clinical Cancer Research in January 2026, this research represents a significant advancement in the fight against pancreatic cancer.

Overall, only about 1 in 10 pancreatic cancer patients survive more than five years from diagnosis; however, experts expect that when the cancer is found and treated at an earlier stage, survival would improve. The challenge has been the absence of effective screening methods—until now.

The Science Behind the Breakthrough

Researchers at the University of Pennsylvania Perelman School of Medicine and Mayo Clinic analyzed banked blood samples from pancreatic cancer patients and healthy individuals. The team found two novel biomarker proteins that were elevated in the blood of early-stage pancreatic cancer patients compared with healthy volunteers: aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR).

They included two blood biomarkers previously explored for use in this way, carbohydrate antigen 19-9 (CA19-9), which is used to monitor treatment response in patients with pancreatic cancer, and thrombospondin 2 (THBS2), another previously used marker, but neither worked well as a screening tool, as CA19-9 can be elevated in people with benign conditions such as pancreatitis and bile duct obstruction while other patients don’t produce it at all due to genetic factors.

The breakthrough came when researchers combined the new markers with existing ones. When they combined ANPEP and PIGR with CA19-9 and THBS2, the four-marker panel successfully distinguished pancreatic cancer cases from non-cases 91.9% of the time across all stages, at a false-positive rate of 5% in non-cases. Importantly, the four-marker test successfully distinguished cancer patients from both healthy individuals and those with non-cancerous pancreatic conditions, such as pancreatitis.

The Path Forward

While early cancer detection is key, there are currently no screening methods to achieve it. This new test could change that paradigm. The retrospective study findings warrant further testing in larger populations, particularly in people before they show symptoms, and such ‘prediagnostic’ studies would help determine if the test could be used as a screening tool for people at high risk of developing the disease based on family history, genetic screening results or personal history of pancreatic cysts or pancreatitis.

Why Early Detection Matters

Early detection is the single most important factor in improving outcomes in pancreatic cancer. When caught at stage I or II, surgical resection offers patients their best chance at long-term survival. The aggressive nature of pancreatic cancer means that even weeks can make a difference in treatment options and prognosis.

This new blood test offers hope not only for those with symptoms but also for high-risk individuals who could benefit from regular screening—a capability that has been urgently needed in the medical community.

5 Pancreatic Cancer FAQs

Q: What are the risk factors for pancreatic cancer?
A: Risk factors include family history of pancreatic cancer, chronic pancreatitis, smoking, obesity, diabetes and certain genetic mutations (BRCA1, BRCA2, Lynch syndrome). Age over 65 also increases risk.

Q: What symptoms should prompt evaluation for pancreatic cancer?
A: Warning signs include jaundice, unexplained weight loss, persistent abdominal or back pain, new-onset diabetes, digestive problems and loss of appetite. However, early-stage disease is often asymptomatic.

Q: Who should consider screening for pancreatic cancer?
A: Individuals with a strong family history (two or more first-degree relatives with pancreatic cancer), known genetic mutations associated with pancreatic cancer or chronic pancreatitis should discuss screening options with their physician.

Q: How is pancreatic cancer currently diagnosed?
A: Diagnosis typically involves imaging studies (CT, MRI, endoscopic ultrasound), blood tests (CA19-9) and tissue biopsy. The new four-marker blood test may soon supplement these methods for earlier detection.

Q: What treatment options exist for pancreatic cancer?
A: Treatment depends on stage and may include surgery (Whipple procedure), chemotherapy, radiation therapy or targeted therapies. Early-stage disease offers the best surgical outcomes and survival rates.

Expert Surgical Care in New York City

When facing a pancreatic cancer diagnosis, choosing an experienced surgeon is critical to achieving the best possible outcome. Dr. Dmitri Alden, MD, FACS, is a renowned surgeon in New York City specializing in complex pancreatic procedures. With extensive expertise in advanced surgical techniques and a commitment to personalized patient care, Dr. Alden provides comprehensive evaluation and treatment for pancreatic conditions.

If you have risk factors for pancreatic cancer or concerning symptoms, don’t wait. Contact Dr. Dmitri Alden’s office today to schedule a consultation and discuss your screening and treatment options. Early detection saves lives—take the first step toward protecting your health.